AIM Immunotech Inc. 10-Q Summary: Quarter Ended September 30, 2025
Business Context and Reporting Period
Company: AIM Immunotech Inc. (AIM)
Reporting Period: Three and nine months ended September 30, 2025
Business Overview: AIM is an immuno-pharma company focused on developing therapeutics for cancers, viral diseases, and immune-deficiency disorders. Its flagship product, Ampligen (rintatolimod), is approved in Argentina for Chronic Fatigue Syndrome (CFS) and is in clinical development for pancreatic cancer, Post-COVID conditions, and as an antiviral. The company also holds Alferon N Injection, an FDA-approved natural alpha-interferon for genital warts, though commercial production is currently on hold.
Key Financial Metrics
| Metric (in thousands) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Total Revenues | $26 | $35 | $67 | $125 |
| Net Loss | $(3,284) | $(3,700) | $(9,783) | $(11,353) |
| Operating Loss | $(2,447) | $(4,489) | $(8,712) | $(13,917) |
| Cash & Equivalents (End of Period) | $2,347 | $915 | $2,347 | $915 |
| Total Assets | $5,494 | $8,608 | $5,494 | $8,608 |
| Total Liabilities | $11,571 | $9,930 | $11,571 | $9,930 |
| Stockholders' Deficit | $(6,077) | $(1,322) | $(6,077) | $(1,322) |
| Warrant Liability | $7,302 | $0 | $7,302 | $0 |
Note: Revenue is derived primarily from the Ampligen Cost Recovery Program. The company reported a significant non-cash loss on the issuance of warrants ($3.977M) and a non-cash gain on the change in fair value of warrants ($0.67M) in Q3 2025.
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased by 11% in Q3 2025 compared to Q3 2024, driven by a $2.33M increase in "Interest and other income" (due to a $3.04M legal fee forgiveness) and reduced operating expenses.
- Expense Reductions: Research and Development (R&D) expenses dropped 58% ($0.83M) and General and Administrative (G&A) expenses dropped 42% ($1.28M) in Q3 2025 year-over-year, reflecting cost-cutting measures.
- Warrant Liability: A new warrant liability of $7.3M was recorded in Q3 2025 following a public offering in July 2025. This was classified as a liability under ASC 480, resulting in a $3.977M non-cash loss on issuance.
- Capital Structure: The company executed a 1-for-100 reverse stock split in June 2025 to regain compliance with NYSE American listing standards. Outstanding shares increased from 655,263 (Dec 2024) to 2,764,188 (Sep 2025) due to the split and new issuances.
- Liquidity: Cash and cash equivalents increased to $2.35M from $1.70M at year-end 2024, supported by $7.67M in financing activities (including an $8M public offering).
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: The filing explicitly states substantial doubt regarding the company's ability to continue as a going concern for one year. This is due to recurring losses, a working capital deficit, and a stockholders' deficit of $6.08M, which is below the NYSE American minimum requirement of $6.0M.
- Listing Compliance: AIM is on a plan to regain compliance with NYSE American equity requirements by June 11, 2026. Failure to do so may result in delisting. Trading was suspended in April 2025 due to low stock price but reinstated in June 2025 following the reverse split.
- Unusual Items:
- Legal Fee Settlement: In Q3 2025, $3.04M of previously billed legal fees were forgiven in exchange for $1.875M in payments, recorded as "other income."
- Warrant Accounting: The July 2025 offering included warrants that triggered a liability classification, creating a significant non-cash loss.
- Clinical Outlook:
- Pancreatic Cancer: The Phase 2 AMP-270 trial was suspended in February 2025 pending data from the ongoing DURIPANC trial (combining Ampligen with durvalumab), which reported positive mid-year safety/efficacy updates in July 2025.
- Post-COVID: Final results from the AMP-518 Phase 2 study support Ampligen's potential for moderate-to-severe Post-COVID fatigue.
Investor Verification Checklist
- Capital Adequacy: Verify the company's ability to raise the necessary capital to meet the $6.0M stockholders' equity requirement by June 2026 to avoid delisting.
- Warrant Liability Impact: Assess the potential dilution and future cash flow impact if the $7.3M warrant liability is exercised or requires cash settlement under specific "Fundamental Transaction" clauses.
- Clinical Trial Status: Confirm the timeline for the resumption or redesign of the suspended AMP-270 pancreatic cancer trial and the progress of the DURIPANC trial.
- Debt Obligations: Review the terms of the Streeterville Capital notes (approx. $1.88M current portion) and the company's ability to service this debt without further equity dilution.
- Argentina Operations: Evaluate the commercial viability of Ampligen sales in Argentina given the country's hyper-inflation and the shift in focus from CFS to pancreatic cancer indications.